News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
732,685 Results
Type
Article (42173)
Company Profile (316)
Press Release (690183)
Multimedia
Podcasts (83)
Webinars (17)
Section
Business (207475)
Career Advice (2062)
Deals (35862)
Drug Delivery (113)
Drug Development (82282)
Employer Resources (175)
FDA (16456)
Job Trends (15129)
News (350595)
Policy (33029)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2599)
Accelerated approval (32)
Adcomms (24)
Allergies (144)
Alliances (50484)
ALS (173)
Alzheimer's disease (1681)
Antibody-drug conjugate (ADC) (313)
Approvals (16727)
Artificial intelligence (524)
Autoimmune disease (155)
Automation (39)
Bankruptcy (364)
Best Places to Work (11706)
BIOSECURE Act (21)
Biosimilars (190)
Biotechnology (212)
Bladder cancer (157)
Brain cancer (56)
Breast cancer (641)
Cancer (4845)
Cardiovascular disease (398)
Career advice (1744)
Career pathing (36)
CAR-T (287)
CDC (44)
Celiac Disease (2)
Cell therapy (760)
Cervical cancer (36)
Clinical research (70285)
Collaboration (1740)
Company closure (4)
Compensation (1166)
Complete response letters (54)
COVID-19 (2738)
CRISPR (93)
C-suite (865)
Cystic fibrosis (143)
Data (6283)
Decentralized trials (2)
Denatured (25)
Depression (135)
Diabetes (503)
Diagnostics (6728)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (258)
Drug pricing (186)
Drug shortages (28)
Duchenne muscular dystrophy (231)
Earnings (90718)
Editorial (59)
Employer branding (21)
Employer resources (154)
Events (120314)
Executive appointments (990)
FDA (19594)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1496)
Gene editing (201)
Generative AI (46)
Gene therapy (615)
GLP-1 (972)
Government (4688)
Grass and pollen (6)
Guidances (383)
Healthcare (18976)
HIV (59)
Huntington's disease (45)
IgA nephropathy (83)
Immunology and inflammation (250)
Immuno-oncology (59)
Indications (111)
Infectious disease (3009)
Inflammatory bowel disease (189)
Inflation Reduction Act (14)
Influenza (117)
Intellectual property (252)
Interviews (319)
IPO (16763)
IRA (50)
Job creations (3762)
Job search strategy (1461)
JPM (57)
Kidney cancer (16)
Labor market (85)
Layoffs (550)
Leadership (32)
Legal (8025)
Liver cancer (91)
Longevity (15)
Lung cancer (650)
Lymphoma (380)
Machine learning (43)
Management (59)
Manufacturing (807)
MASH (163)
Medical device (13794)
Medtech (13847)
Mergers & acquisitions (20174)
Metabolic disorders (1276)
Multiple sclerosis (161)
NASH (16)
Neurodegenerative disease (318)
Neuropsychiatric disorders (89)
Neuroscience (2922)
Neurotech (1)
NextGen: Class of 2026 (6594)
Non-profit (4546)
Now hiring (67)
Obesity (599)
Opinion (269)
Ovarian cancer (166)
Pain (198)
Pancreatic cancer (231)
Parkinson's disease (283)
Partnered (33)
Patents (500)
Patient recruitment (495)
Peanut (57)
People (59983)
Pharmaceutical (68)
Pharmacy benefit managers (29)
Phase 1 (21997)
Phase 2 (30970)
Phase 3 (22923)
Pipeline (5297)
Policy (283)
Postmarket research (2578)
Preclinical (9356)
Press Release (71)
Prostate cancer (239)
Psychedelics (48)
Radiopharmaceuticals (281)
Rare diseases (844)
Real estate (6121)
Recruiting (72)
Regulatory (24707)
Reports (52)
Research institute (2422)
Resumes & cover letters (357)
Rett syndrome (27)
RNA editing (16)
RSV (77)
Schizophrenia (149)
Series A (247)
Series B (197)
Service/supplier (11)
Sickle cell disease (100)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3725)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (86)
The Weekly (56)
Vaccines (1009)
Venture capital (91)
Weight loss (385)
Women's health (91)
Worklife (18)
Date
Last 7 days (612)
Last 30 days (2076)
Last 365 days (30185)
2026 (3461)
2025 (30616)
2024 (35638)
2023 (40431)
2022 (51644)
2021 (56116)
2020 (54496)
2019 (46921)
2018 (35359)
2017 (32540)
2016 (32069)
2015 (38045)
2014 (31822)
2013 (26853)
2012 (29181)
2011 (29859)
2010 (27971)
Location
Africa (766)
Alabama (83)
Alaska (7)
Arizona (312)
Arkansas (13)
Asia (40204)
Australia (6699)
California (11406)
Canada (3294)
China (1120)
Colorado (481)
Connecticut (482)
Delaware (338)
Europe (87314)
Florida (1690)
Georgia (358)
Hawaii (3)
Idaho (61)
Illinois (887)
India (65)
Indiana (522)
Iowa (23)
Japan (434)
Kansas (130)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1388)
Massachusetts (8206)
Michigan (327)
Minnesota (632)
Mississippi (5)
Missouri (128)
Montana (35)
Nebraska (28)
Nevada (122)
New Hampshire (79)
New Jersey (3028)
New Mexico (29)
New York (3005)
North Carolina (1486)
North Dakota (9)
Northern California (5579)
Ohio (334)
Oklahoma (21)
Oregon (41)
Pennsylvania (2295)
Puerto Rico (24)
Rhode Island (48)
South America (1149)
South Carolina (66)
South Dakota (1)
Southern California (4429)
Tennessee (174)
Texas (1755)
United States (40455)
Utah (341)
Vermont (1)
Virginia (263)
Washington D.C. (81)
Washington State (938)
West Virginia (4)
Wisconsin (110)
Wyoming (2)
732,685 Results for "arbor biotechnologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs
October 6, 2025
·
7 min read
Deals
Arbor Biotechnologies Announces Acquisition of Serendipity
Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.
May 8, 2024
·
3 min read
Press Releases
Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors
June 25, 2025
·
2 min read
Press Releases
Arbor Biotechnologies Appoints Don Haut, Ph.D., as Chief Business Officer
May 19, 2025
·
3 min read
Mergers & acquisitions
Chiesi, Arbor Weave $2.1B Rare Disease Pact
The centerpiece of the collaboration is the gene editor ABO-101, being developed for primary hyperoxaluria type 1, a rare disease that leads to severe kidney stones.
October 6, 2025
·
1 min read
·
Tristan Manalac
Gene editing
Arbor Raises $73.5M To Ride Out Gene Editing’s ‘Gartner Hype Cycle’
The gene therapy world is in turmoil, but Arbor, armed with more than $1 billion in partnerships and raises, is going forward.
March 18, 2025
·
4 min read
·
Dan Samorodnitsky
Press Releases
Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1
July 31, 2025
·
5 min read
Press Releases
Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
May 15, 2025
·
6 min read
Business
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Allogene Therapeutics, Inc. and Arbor Biotechnologies, Inc. today announced a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease (AID).
March 12, 2024
·
6 min read
Press Releases
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics
March 18, 2025
·
4 min read
1 of 73,269
Next
